Drug intelligence / Profile preview

EPI-X4-JM-21

Development stage: Preclinical
Lead developer: Pharis Biotec
Modality: Peptides, Small Molecules

Overview

EPI-X4-JM-21 (also referred to as JM#21) is a rationally designed peptide derivative of the endogenous CXCR4 antagonist EPI-X4. It acts as an antagonist of the CXC chemokine receptor type 4 (CXCR4), which is involved in various pathological processes including cancer metastasis, HIV infection, and inflammatory diseases. The drug has been engineered for improved potency and stability compared to its parent compound. Its primary mechanism involves blocking the interaction between CXCR4 and its ligand CXCL12 (SDF-1), thereby inhibiting downstream signaling pathways associated with cell migration and proliferation. The main indications under investigation include cancer and inflammatory disorders[1].

Other names: JM#21EPI-X4-JM-21EPI-X-4-JM-21EPI-X 4-JM-21

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on EPI-X4-JM-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPI-X4-JM-21.

Explore the full profile